FIG. 1.
Least squares mean (SE) changes from baseline for (A) glycosylated hemoglobin (HbA1c), (B) fasting glucose (FG), and (C) body weight. (A) Reduction of HbA1c from baseline with exenatide once weekly (ExQW) treatment was greater than with any other agent. (B) Reduction of FG from baseline with ExQW treatment was greater than with exenatide twice daily (ExBID), sitagliptin, or pioglitazone but less than the reduction seen with insulin glargine. (C) Reduction of body weight with ExQW was similar to that seen with ExBID and greater than that seen with sitagliptin. In contrast, pioglitazone and insulin glargine were both associated with weight gain. *P<0.05.